Aldara activates TLR7-independent immune defence
- PMID: 23463003
- DOI: 10.1038/ncomms2566
Aldara activates TLR7-independent immune defence
Abstract
Aldara is a cream used for topical treatment of non-melanoma skin cancer, and is thought to act through stimulation of anti-tumour immunity. The active ingredient, imiquimod, has been shown to stimulate toll-like receptor 7. Aldara also induces psoriasis-like lesions when applied to naive murine skin, and as such is used as a mouse model for psoriasis. Here we find that in naive murine skin, Aldara induces inflammation largely independently of toll-like receptor 7. Surprisingly, inflammasome activation, keratinocyte death and interleukin 1 release also occur in response to the vehicle cream in the absence of imiquimod. We show that isostearic acid, a major component of the vehicle, promotes inflammasome activation in cultured keratinocytes, and so may contribute to the observed effects of Aldara on murine skin. Aldara therefore stimulates at least two immune pathways independently, and both imiquimod and vehicle are required for a full inflammatory response. Although it remains to be tested, it is possible that imiquimod-independent effects also contribute to the therapeutic efficacy of Aldara.
Similar articles
-
[New perspective in immunotherapy: local imiquimod treatment].Orv Hetil. 2010 May 9;151(19):774-83. doi: 10.1556/OH.2010.28866. Orv Hetil. 2010. PMID: 20427260 Review. Hungarian.
-
Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.J Transl Med. 2007 Jan 26;5:7. doi: 10.1186/1479-5876-5-7. J Transl Med. 2007. PMID: 17257431 Free PMC article. Clinical Trial.
-
Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.J Cutan Pathol. 2005 Apr;32(4):257-62. doi: 10.1111/j.0303-6987.2005.00297.x. J Cutan Pathol. 2005. PMID: 15769273
-
Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.J Immunother. 2011 Apr;34(3):264-9. doi: 10.1097/CJI.0b013e318209eed4. J Immunother. 2011. PMID: 21389872 Free PMC article.
-
Beyond a decade of 5% imiquimod topical therapy.J Drugs Dermatol. 2009 May;8(5):467-74. J Drugs Dermatol. 2009. PMID: 19537370 Review.
Cited by
-
Original Research: Different imiquimod creams resulting in differential effects for imiquimod-induced psoriatic mouse models.Exp Biol Med (Maywood). 2016 Oct;241(16):1733-8. doi: 10.1177/1535370216647183. Epub 2016 Apr 28. Exp Biol Med (Maywood). 2016. PMID: 27190266 Free PMC article.
-
Transmissible Cancers and Immune Downregulation in Tasmanian Devil (Sacrophilus harrisii) and Canine Populations.Comp Med. 2019 Aug 1;69(4):291-298. doi: 10.30802/AALAS-CM-18-000129. Epub 2019 Aug 6. Comp Med. 2019. PMID: 31387668 Free PMC article.
-
Trial Watch: Toll-like receptor agonists for cancer therapy.Oncoimmunology. 2013 Aug 1;2(8):e25238. doi: 10.4161/onci.25238. Epub 2013 Jun 10. Oncoimmunology. 2013. PMID: 24083080 Free PMC article. Review.
-
The Snowballing Literature on Imiquimod-Induced Skin Inflammation in Mice: A Critical Appraisal.J Invest Dermatol. 2017 Mar;137(3):546-549. doi: 10.1016/j.jid.2016.10.024. Epub 2016 Dec 9. J Invest Dermatol. 2017. PMID: 27955901 Free PMC article.
-
The Role of Fibroblast Growth Factor-Binding Protein 1 in Skin Carcinogenesis and Inflammation.J Invest Dermatol. 2018 Jan;138(1):179-188. doi: 10.1016/j.jid.2017.07.847. Epub 2017 Aug 31. J Invest Dermatol. 2018. PMID: 28864076 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous